At #EHA24, we are proud to present data from our Phase III ASC4FIRST trial for patients with newly diagnosed chronic myeloid leukemia (#CML). CML is a type of cancer that develops in the blood-forming cells of the bone marrow. Despite 25+ years of innovation in CML, unmet needs still exist as newly diagnosed patients may fail to meet molecular response goals or discontinue or change treatments due to intolerance. Learn more about Novartis commitment to fighting blood cancers: https://lnkd.in/gvzPZJiQ
Continued innovation is crucial for improving outcomes for newly diagnosed #CML patients. Excited to see the potential impact of this research on addressing unmet needs in CML treatment.
thanks for sharing 💡
Great to see progress in addressing unmet needs for CML patients! Looking forward to learning more about the outcomes from your Phase III ASC4FIRST trial at #EHA24.
Worst company ever!!!! 🙄
মানবদেহের যে কোন জটিল ও কঠিন রোগের অভিজ্ঞ
2mo@https://www.linkedin.com/posts/novartis_unmet-need-in-cml-activity-7207653156971773952-qTRn?utm_source=share&utm_medium=member_android